JP6975860B2 - Ｍｙｓｔファミリーのｋａｔ阻害剤として作用する縮合［１，２，４］チアジアジン誘導体 - Google Patents
Ｍｙｓｔファミリーのｋａｔ阻害剤として作用する縮合［１，２，４］チアジアジン誘導体 Download PDFInfo
- Publication number
- JP6975860B2 JP6975860B2 JP2020533357A JP2020533357A JP6975860B2 JP 6975860 B2 JP6975860 B2 JP 6975860B2 JP 2020533357 A JP2020533357 A JP 2020533357A JP 2020533357 A JP2020533357 A JP 2020533357A JP 6975860 B2 JP6975860 B2 JP 6975860B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- mixture
- lcms
- give
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 O=C(c1c2cccc1)N(CC1c3ccccc3)C2=*2C1=NC=C2 Chemical compound O=C(c1c2cccc1)N(CC1c3ccccc3)C2=*2C1=NC=C2 0.000 description 7
- WWIBVRQWNGUDTG-UHFFFAOYSA-N CCOC(C(N1)=Nc2ccccc2S1(=O)=O)=O Chemical compound CCOC(C(N1)=Nc2ccccc2S1(=O)=O)=O WWIBVRQWNGUDTG-UHFFFAOYSA-N 0.000 description 3
- UKVQBONVSSLJBB-UHFFFAOYSA-N N#CCc1ncccc1 Chemical compound N#CCc1ncccc1 UKVQBONVSSLJBB-UHFFFAOYSA-N 0.000 description 2
- CRCKHDHWVFMLLW-UHFFFAOYSA-N C#Cc(cc1)cc2c1N=C(C(NCC(c1ccccc1)c1ccccc1)=O)NS2 Chemical compound C#Cc(cc1)cc2c1N=C(C(NCC(c1ccccc1)c1ccccc1)=O)NS2 CRCKHDHWVFMLLW-UHFFFAOYSA-N 0.000 description 1
- PSYFOWITOCACIG-UHFFFAOYSA-N C/C=S1/NC(C(NCC(c2ccccc2)c2ccccc2)=O)=Nc2c1cc(C)cc2 Chemical compound C/C=S1/NC(C(NCC(c2ccccc2)c2ccccc2)=O)=Nc2c1cc(C)cc2 PSYFOWITOCACIG-UHFFFAOYSA-N 0.000 description 1
- DPYSDGYWTJJATL-UHFFFAOYSA-N CC(C)(C)OC(NCC(C(NNC(COC)=O)=O)c1ccccc1)=O Chemical compound CC(C)(C)OC(NCC(C(NNC(COC)=O)=O)c1ccccc1)=O DPYSDGYWTJJATL-UHFFFAOYSA-N 0.000 description 1
- QKFYTVJPECAXER-UHFFFAOYSA-N CC(C)(C)OC(NCC(c1nnc(COC)[o]1)c1ccccc1)=O Chemical compound CC(C)(C)OC(NCC(c1nnc(COC)[o]1)c1ccccc1)=O QKFYTVJPECAXER-UHFFFAOYSA-N 0.000 description 1
- BOTWZXCWIIFRJD-UHFFFAOYSA-N CC(C)(C)OC(NCCc(cccc1)c1C(O1)=NNC1=O)=O Chemical compound CC(C)(C)OC(NCCc(cccc1)c1C(O1)=NNC1=O)=O BOTWZXCWIIFRJD-UHFFFAOYSA-N 0.000 description 1
- HTYZMFOOYDLPPT-UHFFFAOYSA-N CC(C)(C)OC(NCCc1ccccc1C(O1)=NN(C)C1=O)=O Chemical compound CC(C)(C)OC(NCCc1ccccc1C(O1)=NN(C)C1=O)=O HTYZMFOOYDLPPT-UHFFFAOYSA-N 0.000 description 1
- NQWPWJAVIQEUJK-UHFFFAOYSA-N CC(COC(C(CN(C(c1ccccc11)=N)C1=O)c1ccccc1)=O)=O Chemical compound CC(COC(C(CN(C(c1ccccc11)=N)C1=O)c1ccccc1)=O)=O NQWPWJAVIQEUJK-UHFFFAOYSA-N 0.000 description 1
- GWNJVELEIJGWIE-UHFFFAOYSA-N CC(c(cc1)cc2c1N=C(C(NCC(c1ncc[o]1)c1ccccc1)=O)NS2(=O)=O)NC Chemical compound CC(c(cc1)cc2c1N=C(C(NCC(c1ncc[o]1)c1ccccc1)=O)NS2(=O)=O)NC GWNJVELEIJGWIE-UHFFFAOYSA-N 0.000 description 1
- JVAGFJQUAKCUNK-UHFFFAOYSA-O CC1(C)OB(C(C=N)=C[NH2+]CCO)OC1(C)C Chemical compound CC1(C)OB(C(C=N)=C[NH2+]CCO)OC1(C)C JVAGFJQUAKCUNK-UHFFFAOYSA-O 0.000 description 1
- TVOJIBGZFYMWDT-UHFFFAOYSA-N CC1(C)OB(c2c[nH]nc2)OC1(C)C Chemical compound CC1(C)OB(c2c[nH]nc2)OC1(C)C TVOJIBGZFYMWDT-UHFFFAOYSA-N 0.000 description 1
- VIPGMSCSZQMCFQ-UHFFFAOYSA-N CCC(O1)=NN(C)C1=O Chemical compound CCC(O1)=NN(C)C1=O VIPGMSCSZQMCFQ-UHFFFAOYSA-N 0.000 description 1
- LXFXOBAJNRFRIC-UHFFFAOYSA-N CCOC(C(CC(S(c1c2)(=O)=O)=C)=Nc1ccc2C#C[Si](C)(C)C)=O Chemical compound CCOC(C(CC(S(c1c2)(=O)=O)=C)=Nc1ccc2C#C[Si](C)(C)C)=O LXFXOBAJNRFRIC-UHFFFAOYSA-N 0.000 description 1
- XJSVMJSOWKHJBZ-UHFFFAOYSA-N CCOC(C(N1)=C=Cc(ccc(I)c2)c2/S1=C\C)=O Chemical compound CCOC(C(N1)=C=Cc(ccc(I)c2)c2/S1=C\C)=O XJSVMJSOWKHJBZ-UHFFFAOYSA-N 0.000 description 1
- IBDQLJPLYIRNCS-UHFFFAOYSA-N CCOC(C(N1C)=Nc(cccc2)c2S1(=O)=O)=O Chemical compound CCOC(C(N1C)=Nc(cccc2)c2S1(=O)=O)=O IBDQLJPLYIRNCS-UHFFFAOYSA-N 0.000 description 1
- BGPRDUCVNKELLY-UHFFFAOYSA-N CCOC(C(Nc(c(S(N)(=O)=O)c1)ccc1F)=O)=O Chemical compound CCOC(C(Nc(c(S(N)(=O)=O)c1)ccc1F)=O)=O BGPRDUCVNKELLY-UHFFFAOYSA-N 0.000 description 1
- QOFAIFKSKKFEID-UHFFFAOYSA-O CCOC(C([NH3+])=Nc(cccc1)c1S(C)(=O)=O)=O Chemical compound CCOC(C([NH3+])=Nc(cccc1)c1S(C)(=O)=O)=O QOFAIFKSKKFEID-UHFFFAOYSA-O 0.000 description 1
- XMDUHEPXFVWTGG-UHFFFAOYSA-N COC(c(cc1)cc2c1N=C(C(NCC(c1ncc[o]1)c1ccccc1)=O)NS2(=O)=O)=O Chemical compound COC(c(cc1)cc2c1N=C(C(NCC(c1ncc[o]1)c1ccccc1)=O)NS2(=O)=O)=O XMDUHEPXFVWTGG-UHFFFAOYSA-N 0.000 description 1
- UJAFBEMYWFLDLV-UHFFFAOYSA-N COCc1nnc(C(CN)c2ccccc2)[o]1 Chemical compound COCc1nnc(C(CN)c2ccccc2)[o]1 UJAFBEMYWFLDLV-UHFFFAOYSA-N 0.000 description 1
- KXWGKPBECUHFAZ-UHFFFAOYSA-N C[Si+](C)(C)C#Cc(cc12)ccc1N=C(C(NCC(c1ccccc1)c1ccccc1)=O)NS2(=O)=O Chemical compound C[Si+](C)(C)C#Cc(cc12)ccc1N=C(C(NCC(c1ccccc1)c1ccccc1)=O)NS2(=O)=O KXWGKPBECUHFAZ-UHFFFAOYSA-N 0.000 description 1
- AIEWCGGMKZLWIM-UHFFFAOYSA-N Cc1c[o]c(C(CN)c2ccccc2)n1 Chemical compound Cc1c[o]c(C(CN)c2ccccc2)n1 AIEWCGGMKZLWIM-UHFFFAOYSA-N 0.000 description 1
- ODZSKQKKIPBCSM-UHFFFAOYSA-N Cc1c[o]c(C(CNC(C(N2)=Nc(cccc3)c3S2(=O)=O)=O)c2ccccc2)n1 Chemical compound Cc1c[o]c(C(CNC(C(N2)=Nc(cccc3)c3S2(=O)=O)=O)c2ccccc2)n1 ODZSKQKKIPBCSM-UHFFFAOYSA-N 0.000 description 1
- RXKMMFGVXOEAMT-UHFFFAOYSA-N Cc1nnc(C(CN)c2ccccc2)[o]1 Chemical compound Cc1nnc(C(CN)c2ccccc2)[o]1 RXKMMFGVXOEAMT-UHFFFAOYSA-N 0.000 description 1
- DVPHEPHLDCLXTE-UHFFFAOYSA-N Clc1cccc(Cc2ncc[o]2)c1 Chemical compound Clc1cccc(Cc2ncc[o]2)c1 DVPHEPHLDCLXTE-UHFFFAOYSA-N 0.000 description 1
- MRLREHCMBWHUHY-UHFFFAOYSA-N N#CC1(CCCC1)c1ncccc1 Chemical compound N#CC1(CCCC1)c1ncccc1 MRLREHCMBWHUHY-UHFFFAOYSA-N 0.000 description 1
- JJBRLQGIVCSMJR-UHFFFAOYSA-N N#CC1(CCCCC1)c1ccccn1 Chemical compound N#CC1(CCCCC1)c1ccccn1 JJBRLQGIVCSMJR-UHFFFAOYSA-N 0.000 description 1
- UTLRETGJEPCEDU-UHFFFAOYSA-N NCC(c1ncc[o]1)c1ccccc1 Chemical compound NCC(c1ncc[o]1)c1ccccc1 UTLRETGJEPCEDU-UHFFFAOYSA-N 0.000 description 1
- OGCQLDSZOXAYGK-UHFFFAOYSA-N NCC(c1nnc[o]1)c1ccccc1 Chemical compound NCC(c1nnc[o]1)c1ccccc1 OGCQLDSZOXAYGK-UHFFFAOYSA-N 0.000 description 1
- DQSRGJUPRBBWIV-UHFFFAOYSA-N NCC1(CCCC1)c1ccccn1 Chemical compound NCC1(CCCC1)c1ccccn1 DQSRGJUPRBBWIV-UHFFFAOYSA-N 0.000 description 1
- XGYWBGLMCUFVOB-UHFFFAOYSA-N NCC1(CCCCC1)c1ccccn1 Chemical compound NCC1(CCCCC1)c1ccccn1 XGYWBGLMCUFVOB-UHFFFAOYSA-N 0.000 description 1
- KXTMEODRUCUIJI-UHFFFAOYSA-N NCCc1ccccc1C#N Chemical compound NCCc1ccccc1C#N KXTMEODRUCUIJI-UHFFFAOYSA-N 0.000 description 1
- VBZCQORAEBTLIV-UHFFFAOYSA-M Nc1ccccc1CC[N-]C(C(N1)=Nc(cccc2)c2S1(=O)=O)=O Chemical compound Nc1ccccc1CC[N-]C(C(N1)=Nc(cccc2)c2S1(=O)=O)=O VBZCQORAEBTLIV-UHFFFAOYSA-M 0.000 description 1
- XRMWYCDZHQFSTB-UHFFFAOYSA-N O=C(C(N1)=Nc(ccc(Br)c2)c2S1(=O)=O)NCC(c1ccccc1)c1ccccc1 Chemical compound O=C(C(N1)=Nc(ccc(Br)c2)c2S1(=O)=O)NCC(c1ccccc1)c1ccccc1 XRMWYCDZHQFSTB-UHFFFAOYSA-N 0.000 description 1
- FUGRFABXYKPPOY-UHFFFAOYSA-N O=C(C(N1)=Nc(ccc(Br)c2)c2S1(=O)=O)NCC(c1ncc[o]1)c1ccccc1 Chemical compound O=C(C(N1)=Nc(ccc(Br)c2)c2S1(=O)=O)NCC(c1ncc[o]1)c1ccccc1 FUGRFABXYKPPOY-UHFFFAOYSA-N 0.000 description 1
- BBFZLNLMJTVQSL-UHFFFAOYSA-N O=C(C(N1)=Nc(cccc2)c2S1(=O)=O)NCC(c1nnc[o]1)c1ccccc1 Chemical compound O=C(C(N1)=Nc(cccc2)c2S1(=O)=O)NCC(c1nnc[o]1)c1ccccc1 BBFZLNLMJTVQSL-UHFFFAOYSA-N 0.000 description 1
- PYPMKORNJLTHGP-UHFFFAOYSA-N O=C(Cc1cc(Cl)ccc1)Cl Chemical compound O=C(Cc1cc(Cl)ccc1)Cl PYPMKORNJLTHGP-UHFFFAOYSA-N 0.000 description 1
- SLQRTLNEPYHBST-UHFFFAOYSA-N O=C(c1c2cccc1)N(CC(c1ccccc1)[n]1nncc1)C2=O Chemical compound O=C(c1c2cccc1)N(CC(c1ccccc1)[n]1nncc1)C2=O SLQRTLNEPYHBST-UHFFFAOYSA-N 0.000 description 1
- LCJLRBKGKKCGFY-UHFFFAOYSA-N O=C(c1c2cccc1)N(CC(c1ncc[o]1)c1cccc(Cl)c1)C2=O Chemical compound O=C(c1c2cccc1)N(CC(c1ncc[o]1)c1cccc(Cl)c1)C2=O LCJLRBKGKKCGFY-UHFFFAOYSA-N 0.000 description 1
- YSYXKPJJQWEYSO-UHFFFAOYSA-N OC(C(CN(C(c1c2cccc1)=O)C2=O)c1ccccc1)=O Chemical compound OC(C(CN(C(c1c2cccc1)=O)C2=O)c1ccccc1)=O YSYXKPJJQWEYSO-UHFFFAOYSA-N 0.000 description 1
- DLCJOWUYWJUGDE-UHFFFAOYSA-N OC(C(CN(C(c1ccccc11)=O)C1=[U])c1ccccc1)=O Chemical compound OC(C(CN(C(c1ccccc11)=O)C1=[U])c1ccccc1)=O DLCJOWUYWJUGDE-UHFFFAOYSA-N 0.000 description 1
- WFPMUFXQDKMVCO-UHFFFAOYSA-N OC(Cc1cccc(Cl)c1)=O Chemical compound OC(Cc1cccc(Cl)c1)=O WFPMUFXQDKMVCO-UHFFFAOYSA-N 0.000 description 1
- HGKHIWWSLIXTCA-UHFFFAOYSA-N OC(c(cc1)cc2c1N=C(C(NCC(c1ncc[o]1)c1ccccc1)=O)NS2)=O Chemical compound OC(c(cc1)cc2c1N=C(C(NCC(c1ncc[o]1)c1ccccc1)=O)NS2)=O HGKHIWWSLIXTCA-UHFFFAOYSA-N 0.000 description 1
- BELFSZVBAUCBCM-UHFFFAOYSA-N OC(c1ccccc1CCNC(C(N1)=Nc(ccc(I)c2)c2S1(=O)=O)=O)=O Chemical compound OC(c1ccccc1CCNC(C(N1)=Nc(ccc(I)c2)c2S1(=O)=O)=O)=O BELFSZVBAUCBCM-UHFFFAOYSA-N 0.000 description 1
- KHOQBANSLKKMON-UHFFFAOYSA-N OCC[n]1ncc(-c(cc23)ccc2N=C(C(NCC(c2ncc[o]2)c2ccccc2)=O)NS3(=O)=O)c1 Chemical compound OCC[n]1ncc(-c(cc23)ccc2N=C(C(NCC(c2ncc[o]2)c2ccccc2)=O)NS3(=O)=O)c1 KHOQBANSLKKMON-UHFFFAOYSA-N 0.000 description 1
- SYAJPCLYIXFLHJ-UHFFFAOYSA-N OCc1ccccc1CCNC1C(C(N2)=Nc(ccc(I)c3)c3S2(=O)=O)OC1 Chemical compound OCc1ccccc1CCNC1C(C(N2)=Nc(ccc(I)c3)c3S2(=O)=O)OC1 SYAJPCLYIXFLHJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1713962.7A GB201713962D0 (en) | 2017-08-31 | 2017-08-31 | Compounds |
| GB1713962.7 | 2017-08-31 | ||
| PCT/EP2018/073431 WO2019043139A1 (en) | 2017-08-31 | 2018-08-31 | FUSED [1,2,4] THIADIAZINE DERIVATIVES AS KAT INHIBITORS OF THE MYST FAMILY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531593A JP2020531593A (ja) | 2020-11-05 |
| JP2020531593A5 JP2020531593A5 (enExample) | 2021-10-14 |
| JP6975860B2 true JP6975860B2 (ja) | 2021-12-01 |
Family
ID=60050736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533357A Expired - Fee Related JP6975860B2 (ja) | 2017-08-31 | 2018-08-31 | Ｍｙｓｔファミリーのｋａｔ阻害剤として作用する縮合［１，２，４］チアジアジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210380548A1 (enExample) |
| EP (1) | EP3676266A1 (enExample) |
| JP (1) | JP6975860B2 (enExample) |
| CA (1) | CA3073794A1 (enExample) |
| GB (1) | GB201713962D0 (enExample) |
| WO (1) | WO2019043139A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112028850B (zh) * | 2019-06-03 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种帕瑞昔布钠的中间体化合物 |
| CN112028851B (zh) * | 2019-06-03 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种帕瑞昔布钠中间体化合物 |
| WO2021030278A1 (en) * | 2019-08-12 | 2021-02-18 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| CA3189410A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Kat6 inhibitor methods and combinations for cancer treatment |
| CN117597341A (zh) | 2021-08-10 | 2024-02-23 | 江苏恒瑞医药股份有限公司 | 磺酰胺衍生物、其制备方法及其在医药上的应用 |
| EP4561571A1 (en) | 2022-07-29 | 2025-06-04 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
| EP4663635A1 (en) | 2023-02-10 | 2025-12-17 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of sulfonamide derivative and preparation method therefor |
| CN120981721A (zh) | 2023-03-30 | 2025-11-18 | 辉瑞大药厂 | Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002514192A (ja) * | 1996-11-13 | 2002-05-14 | セフアロン・インコーポレーテツド | ベンゾチアゾおよび関連の複素環基を含有するシステインおよびセリンプロテアーゼ阻害剤 |
| DE102005055355A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
| GB201510019D0 (en) * | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
-
2017
- 2017-08-31 GB GBGB1713962.7A patent/GB201713962D0/en not_active Ceased
-
2018
- 2018-08-31 US US16/642,290 patent/US20210380548A1/en not_active Abandoned
- 2018-08-31 EP EP18762297.2A patent/EP3676266A1/en not_active Withdrawn
- 2018-08-31 JP JP2020533357A patent/JP6975860B2/ja not_active Expired - Fee Related
- 2018-08-31 WO PCT/EP2018/073431 patent/WO2019043139A1/en not_active Ceased
- 2018-08-31 CA CA3073794A patent/CA3073794A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020531593A (ja) | 2020-11-05 |
| GB201713962D0 (en) | 2017-10-18 |
| EP3676266A1 (en) | 2020-07-08 |
| US20210380548A1 (en) | 2021-12-09 |
| CA3073794A1 (en) | 2019-03-07 |
| WO2019043139A1 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6975860B2 (ja) | Ｍｙｓｔファミリーのｋａｔ阻害剤として作用する縮合［１，２，４］チアジアジン誘導体 | |
| JP7692095B2 (ja) | 化合物 | |
| KR100957516B1 (ko) | 2ｈ-프탈라진-1-온 및 이것의 사용 방법 | |
| ES2855135T3 (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| JP4764823B2 (ja) | キナーゼ阻害剤としての１，６−二置換アザベンゾイミダゾールの調製 | |
| EP1720864B1 (en) | Benzimidazol substituted thiophene derivatives with activity on ikk3 | |
| CN101790527A (zh) | Rho激酶的苯并噻吩抑制剂 | |
| KR20170072242A (ko) | 질환의 치료를 위한 헤파란 설페이트 생합성 억제제 | |
| CN102026992A (zh) | 新的hsp90抑制性咔唑衍生物和含有该咔唑衍生物的组合物及其用途 | |
| JP6559699B2 (ja) | 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用 | |
| ES2375588T3 (es) | Quinolinas y su uso terapéutico. | |
| JP2016537324A (ja) | シクロペンチルベンズアミド誘導体及びそれらの精神障害及び認知障害の治療への使用 | |
| KR20140117651A (ko) | 이소퀴놀린 및 나프티리딘 유도체 | |
| JP2019001715A (ja) | 三環性化合物 | |
| US20080194561A1 (en) | Compounds | |
| WO2012121168A1 (ja) | キナーゼ阻害剤 | |
| RU2838187C2 (ru) | Соединения | |
| CN119604287A (zh) | 杂环pad4抑制剂 | |
| TW202140467A (zh) | 小分子干擾素基因刺激因子(sting)拮抗劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210831 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210831 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210831 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211019 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211108 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6975860 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |